Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms

Abstract The efficacy of sonodynamic therapy (SDT), an emerging approach for tumor treatment, is hindered by the high levels of the antioxidant glutathione (GSH) in the tumor microenvironment (TME). In this study, we constructed nanobubbles loaded with the sonosensitizer HMME and the tumor-targeting...

Full description

Saved in:
Bibliographic Details
Main Authors: Yucao Sun, Yichi Chen, Bolin Wu, Helin Li, Yijun Wang, Xiaodong Wang, Liwen Deng, Kuikun Yang, Xiuhong Wang, Wen Cheng
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Journal of Nanobiotechnology
Subjects:
Online Access:https://doi.org/10.1186/s12951-024-02995-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850254083006398464
author Yucao Sun
Yichi Chen
Bolin Wu
Helin Li
Yijun Wang
Xiaodong Wang
Liwen Deng
Kuikun Yang
Xiuhong Wang
Wen Cheng
author_facet Yucao Sun
Yichi Chen
Bolin Wu
Helin Li
Yijun Wang
Xiaodong Wang
Liwen Deng
Kuikun Yang
Xiuhong Wang
Wen Cheng
author_sort Yucao Sun
collection DOAJ
description Abstract The efficacy of sonodynamic therapy (SDT), an emerging approach for tumor treatment, is hindered by the high levels of the antioxidant glutathione (GSH) in the tumor microenvironment (TME). In this study, we constructed nanobubbles loaded with the sonosensitizer HMME and the tumor-targeting peptide RGD (HMME-RGD@C3F8 NBs) for synergistic SDT/cuproptosis therapy of liver hepatocellular carcinoma (LIHC) in combination with Elesclomol-Cu as cuproptosis inducers. Endogenous GSH is consumed by Cu2+ to modulate the complex TME, thereby amplifying oxidative stress and further improving SDT performance. Additionally, intracellular Cu2+ overload can induce cuproptosis, which is further amplified by SDT, to initiate irreversible protein toxicity. The specific mechanism of synergistic SDT/cuproptosis therapy in LIHC was investigated by RNA sequencing analysis. The synergistic SDT/cuproptosis therapy reprogrammed the TME to improve the efficacy of immune checkpoint inhibitor-based immunotherapy. Furthermore, a risk-scoring model was created and displayed significant promise in the prognosis of LIHC. Graphical Abstract
format Article
id doaj-art-b27aa57a9f9744ac954b21d79d02e433
institution OA Journals
issn 1477-3155
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series Journal of Nanobiotechnology
spelling doaj-art-b27aa57a9f9744ac954b21d79d02e4332025-08-20T01:57:12ZengBMCJournal of Nanobiotechnology1477-31552024-12-0122111810.1186/s12951-024-02995-3Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanismsYucao Sun0Yichi Chen1Bolin Wu2Helin Li3Yijun Wang4Xiaodong Wang5Liwen Deng6Kuikun Yang7Xiuhong Wang8Wen Cheng9Department of Ultrasound, Department of Interventional Ultrasound, Harbin Medical University Cancer HospitalDepartment of Ultrasound, Department of Interventional Ultrasound, Harbin Medical University Cancer HospitalDepartment of Ultrasound, Department of Interventional Ultrasound, Harbin Medical University Cancer HospitalDepartment of Ultrasound, Department of Interventional Ultrasound, Harbin Medical University Cancer HospitalDepartment of Ultrasound, Department of Interventional Ultrasound, Harbin Medical University Cancer HospitalDepartment of Ultrasound, Department of Interventional Ultrasound, Harbin Medical University Cancer HospitalDepartment of Ultrasound, Department of Interventional Ultrasound, Harbin Medical University Cancer HospitalSchool of Life Science and Technology, Harbin Institute of TechnologyDepartment of Biochemistry and Molecular Biology, Heilongjiang Provincial Science and Technology Innovation Team in Higher Education Institutes for Infection and Immunity, Harbin Medical UniversityDepartment of Ultrasound, Department of Interventional Ultrasound, Harbin Medical University Cancer HospitalAbstract The efficacy of sonodynamic therapy (SDT), an emerging approach for tumor treatment, is hindered by the high levels of the antioxidant glutathione (GSH) in the tumor microenvironment (TME). In this study, we constructed nanobubbles loaded with the sonosensitizer HMME and the tumor-targeting peptide RGD (HMME-RGD@C3F8 NBs) for synergistic SDT/cuproptosis therapy of liver hepatocellular carcinoma (LIHC) in combination with Elesclomol-Cu as cuproptosis inducers. Endogenous GSH is consumed by Cu2+ to modulate the complex TME, thereby amplifying oxidative stress and further improving SDT performance. Additionally, intracellular Cu2+ overload can induce cuproptosis, which is further amplified by SDT, to initiate irreversible protein toxicity. The specific mechanism of synergistic SDT/cuproptosis therapy in LIHC was investigated by RNA sequencing analysis. The synergistic SDT/cuproptosis therapy reprogrammed the TME to improve the efficacy of immune checkpoint inhibitor-based immunotherapy. Furthermore, a risk-scoring model was created and displayed significant promise in the prognosis of LIHC. Graphical Abstracthttps://doi.org/10.1186/s12951-024-02995-3CuproptosisSonodynamic therapyLiver hepatocellular carcinomaSynergistic tumor therapyRNA sequencing
spellingShingle Yucao Sun
Yichi Chen
Bolin Wu
Helin Li
Yijun Wang
Xiaodong Wang
Liwen Deng
Kuikun Yang
Xiuhong Wang
Wen Cheng
Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms
Journal of Nanobiotechnology
Cuproptosis
Sonodynamic therapy
Liver hepatocellular carcinoma
Synergistic tumor therapy
RNA sequencing
title Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms
title_full Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms
title_fullStr Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms
title_full_unstemmed Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms
title_short Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms
title_sort synergistic sdt cuproptosis therapy for liver hepatocellular carcinoma enhanced antitumor efficacy and specific mechanisms
topic Cuproptosis
Sonodynamic therapy
Liver hepatocellular carcinoma
Synergistic tumor therapy
RNA sequencing
url https://doi.org/10.1186/s12951-024-02995-3
work_keys_str_mv AT yucaosun synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT yichichen synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT bolinwu synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT helinli synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT yijunwang synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT xiaodongwang synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT liwendeng synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT kuikunyang synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT xiuhongwang synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms
AT wencheng synergisticsdtcuproptosistherapyforliverhepatocellularcarcinomaenhancedantitumorefficacyandspecificmechanisms